Wyndham Wilson, MD
Enriched profileHead, Lymphoma Therapeutics Section, and Senior Investigator, Lymphoid Malignancies Branch, National Cancer Institute · National Cancer Institute (NCI)
Wyndham Wilson is Head, Lymphoma Therapeutics Section, and Senior Investigator, Lymphoid Malignancies Branch, National Cancer Institute at National Cancer Institute (NCI). OpenAlex indexes 600 publications with 60,661 citations (h-index 103); ClinicalTrials.gov lists 13 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Medical Oncology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Wyndham Wilson, MD, PHD, is Head, Lymphoma Therapeutics Section, and Senior Investigator, Lymphoid Malignancies Branch, National Cancer Institute. The public record shows 600 publications with 60,661 citations (h-index 103), centered on Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, Viral-associated cancers and disorders. It also documents an investigator role on 13 registered clinical trials.
- Top research focus: Lymphoma Diagnosis and Treatment
- 13 registered trials on ClinicalTrials.gov
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 7 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 284.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 13 registered studies on ClinicalTrials.gov. The most recent:
- Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas
Sponsor: National Cancer Institute (NCI)
- MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma
Sponsor: National Cancer Institute (NCI)
- Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas
Sponsor: National Cancer Institute (NCI)
Industry payments
No payments involving this person were reported to CMS in program years 2021–2024. Why? →
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 27 Aug 2026
84 congress contributions (2004–2025) across AACR, ASCO, ASH per OpenAlex. The most recent:
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
None on file yet. We only list publications we can confidently match to this person. Why? →
Most-cited works
by citation count (OpenAlex)- 01Distinct types of diffuse large B-cell lymphoma identified by gene expression profilingArticle9,972 citations2000
- 02The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell LymphomaArticle3,864 citations2002
- 03Genetics and Pathogenesis of Diffuse Large B-Cell LymphomaArticle2,289 citations2018
- 04Stromal Gene Signatures in Large-B-Cell LymphomasArticle1,831 citations2008
- 05Chronic active B-cell-receptor signalling in diffuse large B-cell lymphomaArticle1,656 citations2010
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/wyndham-wilson-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →irp.nih.gov ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →irp.nih.gov ↗
- Board Certified
Medical Oncology (American Board of Internal Medicine)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →health.usnews.com ↗
Editorial & leadership roles
journal and society appointments- Past Chair
FDA Oncologic Drug Advisory Committee
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗ - Past Chair
NCI Institutional Review Board
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →foundationforburkittlymphoma.org ↗ - Member
Lymphoma Steering Committee, Cooperative Groups of the Cancer Therapy Evaluation Program, NCI/NIH
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →foundationforburkittlymphoma.org ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ecancer.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vjhemonc.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Stephen Chanock, MD
National Cancer Institute (NCI)
Seth Steinberg, PhD
National Cancer Institute (NCI)
Kevin Camphausen, MD
National Cancer Institute (NCI)